A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2016-02-03
Target enrollment:
Participant gender:
Summary
This study was supposed to have assessed the safety and preliminary antitumor activity of
CFG920, a new CYP17 inhibitor in castration resistant prostate cancer patients who are
abiraterone naive or abiraterone resistant.
The study was terminated after Phase I (dose escalation phase) and Phase II part of the study
was not initiated. Novartis voluntarily terminated this study and hence stopped further
enrollment of patients into this study. As the decision to terminate the study was not due to
any safety issues, the patients enrolled in the study by the time of this decision were
allowed to continue with treatment per the protocol.